Actively Recruiting

Phase 1
Age: 18Years - 60Years
All Genders
NCT06400862

Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

Led by Chinese University of Hong Kong · Updated on 2024-05-06

9

Participants Needed

2

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The objective of the study is to establish the safety profile of the autologous engineered osteochondral tissues (eOCT) in treating traumatic chondral lesions in patients.

CONDITIONS

Official Title

Treating Patients With Traumatic Chondral Lesions With Autologous Bone Marrow Cells Derived Engineered Tissues - Engineered Osteochondral Tissue

Who Can Participate

Age: 18Years - 60Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 60 years
  • Single symptomatic cartilage defect on medial or lateral femoral condyle
  • Contained single focal cartilage lesion approximately 1-4 cm squared
  • Cartilage damage graded as ICRS/Outerbridge grade III or IV reaching subchondral bone confirmed by MRI
  • Failure of conservative treatments for more than 4 months
Not Eligible

You will not qualify if you...

  • Previous cartilage repair surgery (OATS or ACI/MACI) in the affected knee
  • Injection treatments such as HA, PRP, or stem cells in the affected knee within 3 months before consent
  • Clinically relevant patellofemoral cartilage lesion in the affected knee
  • Inflammatory joint diseases including specific or non-specific arthritis
  • Metabolic diseases such as gout or rheumatism
  • Advanced osteoarthritis with Kellgren & Lawrence grade greater than 2
  • Osteochondritis dissecans
  • Multiple or uncontained cartilage lesions detected by MRI or arthroscopy
  • Uncorrected ligament deficiency
  • Uncorrected varus or valgus malalignment exceeding 5 degrees
  • Ongoing infection or skin disease at the target knee
  • Significant meniscal loss
  • Unable or unwilling to provide written informed consent
  • Skeletal immaturity
  • Pregnant or lactating females
  • Body mass index over 30 kg/m2
  • Malignancy
  • Recent steroid therapy within 30 to 60 days before consent depending on route
  • Contraindications to MRI
  • Drug addiction including narcotics, anesthetics, or alcohol
  • High risk for post-surgical bleeding or infection
  • Allergy to porcine or bovine collagen
  • Painful or disabling diseases of spine, hips, or lower limbs affecting knee evaluation
  • Infections such as HIV, hepatitis, or syphilis
  • Significant vascular or neurologic disorders of lower extremities
  • Poor general health as judged by investigator
  • Inability to complete follow-up visits

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Queen Elizabeth Hospital

Jordon, Hong Kong

Actively Recruiting

2

Prince of Wales Hospital

Shatin, Hong Kong

Actively Recruiting

Loading map...

Research Team

B

Barbara Pui CHAN, PhD

CONTACT

Y

Yinan QIU, Master

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here